Guangdong True Health Medical Technology Development Co., Ltd. (Ticker: 2697 HK) is a China-domiciled medical device company developing and commercializing surgical robots and related equipment used in minimally invasive procedures. Its main product is a percutaneous puncture surgical robot, which helps doctors guide needles through the skin to reach areas such as the lung or abdomen for diagnosis or treatment. The company also develops microwave ablation robots, which use heat to destroy tumor tissue, cryoablation robots, which use freezing, and organ preservation systems.

Guangdong True Health Medical Technology is expected to list H shares on the Hong Kong Stock Exchange on June 30, 2026, with pricing expected on June 26, 2026. The company plans to offer 3.56 million shares at an expected price range of HKD 119.30 to HKD 135.60 per share, raising up to approximately HKD 483 million, or approximately $62 million. The offering consists entirely of primary shares and includes a 15% greenshoe option.

According to the prospectus, the company was founded in 2018 and has NMPA Class III registrations for several models of its puncture surgical robot. Joint managers include ABCI Capital, CMBC Securities, CICC and DBS Asia Capital.